Table 1.
Clinicopathological Characteristics of the Studied Patients.
| N = 137 | ||
|---|---|---|
| Characteristics | n | % |
| Gender | ||
| Male | 85 | 62.0 |
| Female | 52 | 38.0 |
| Age | ||
| ≤58 | 66 | 48.2 |
| >58 | 71 | 51.8 |
| Smoking status | ||
| No | 76 | 55.5 |
| Yes | 61 | 44.5 |
| PET/CT stage | ||
| I and II | 25 | 18.2 |
| III | 40 | 29.2 |
| IV | 72 | 52.6 |
| Histology | ||
| Adenocarcinoma | 90 | 65.7 |
| Squamous cell carcinoma | 29 | 21.2 |
| Poorly differentiated NSCLC | 15 | 10.9 |
| Others | 3 | 2.2 |
| Differentiation degree | ||
| Well-differentiated | 4 | 2.9 |
| Moderately differentiated | 10 | 7.3 |
| Poorly differentiated | 37 | 27.0 |
| Not checked | 86 | 62.8 |
| Type of surgery | ||
| Lobectomy | 28 | 20.4 |
| Pneumonectomy | 3 | 2.2 |
| Others | 6 | 4.4 |
| No surgery | 100 | 73.0 |
| Chemotherapy regimen | ||
| PMX-based | 58 | 42.3 |
| PTX-based | 35 | 25.5 |
| GEMZ-based | 19 | 13.9 |
| TXT-based | 16 | 11.7 |
| Others | 9 | 6.6 |
| Adjuvant radiotherapy | ||
| No | 67 | 48.9 |
| Yes | 70 | 51.1 |
| Targeted therapy | ||
| No | 100 | 73.0 |
| Yes | 37 | 27.0 |
Abbreviations: CT, computed tomography; GEMZ, gemcitabine; NSCLC, non-small cell lung cancer; PET, positron emission tomography; PMX, pemetrexed; PTX, paclitaxel; TXT, docetaxel.